TB-500 · cycle length · research use only
How long is a TB-500 cycle? Loading, maintenance, and what the data actually supports.
TB-500 protocols are almost always described with a shape BPC-157 protocols don't have: an initial higher-frequency 'loading' block of several weeks, followed by a spaced-out 'maintenance' phase, and then a break. That structure isn't arbitrary — it's inferred from the compound's kinetics. TB-500 (the synthetic fragment Ac-LKKTETQ, corresponding to residues 17–23 of Thymosin β4) is associated with prolonged tissue persistence relative to its short plasma presence, which is the usual justification for front-loading and then dosing less often. But 'inferred from a half-life' is not the same as 'proven in a trial', and there is a second honesty problem specific to TB-500: there is no dedicated human cycle study of the fragment at all — most of the human safety and duration evidence people cite actually belongs to full-length Thymosin β4 (for example the RGN-259 ophthalmic program), a different molecule. This page lays out the loading/maintenance convention, where it comes from, and where the evidence stops. It is a research reference, not a human-use schedule and not medical advice.
The loading / maintenance shape (and why it exists)
TB-500 protocols are typically written in two phases: a 'loading' block — higher weekly frequency for roughly the first 4–6 weeks — followed by a 'maintenance' phase at a lower frequency, then a rest period. The stated rationale is kinetic: because the fragment is associated with prolonged tissue residence, front-loading is meant to reach a working tissue level, after which less frequent dosing is thought to sustain it. It's a coherent inference from the half-life — but it is an inference from convention, not a schedule any controlled human trial validated.
See the research dose ranges →The half-life is the driver — and it cuts both ways
TB-500's defining kinetic feature is the gap between a short plasma presence and a much longer tissue persistence. That long tail is exactly what the maintenance-phase convention leans on: dose often to load, then rarely to hold. But the same long persistence is why open-ended stacking is cautioned against — material lingers, so 'more, indefinitely' is not obviously better. The cycle shape is genuinely a half-life story, unlike BPC-157, whose cycling convention rests mostly on missing long-term data.
TB-500 half-life explained →The data you're quoting is probably Thymosin β4, not TB-500
This is the single most important honesty point on the page. TB-500 is a short synthetic fragment; the bulk of controlled human safety and dosing-duration evidence belongs to full-length Thymosin β4 — a larger, different molecule studied in programs like RGN-259 (ophthalmic) and early-phase safety work. Extrapolating those durations to the fragment is a leap most vendor pages make silently. Any TB-500 cycle figure presented as clinically-backed is almost certainly borrowing the parent peptide's record.
Safety data — parent vs fragment →So what's the honest cycle length?
Unknown, in any validated sense. The commonly-repeated structure — ~4–6 weeks loading, several weeks maintenance, then off — is protocol convention, coherent with the kinetics but not established by a fragment-specific human trial. Treat published figures as the field's shared framework for organising these protocols, not as a proven optimum. Where a source states a specific TB-500 cycle length as fact, ask whether it's citing the fragment or quietly importing Thymosin β4 data.
TB-500 results timeline →The duration a lab can control: reconstituted stability
As with any lyophilised peptide, the one duration a laboratory genuinely controls isn't the 'cycle' — it's how long the reconstituted vial stays intact. Lyophilised TB-500 reference material is stable for months under controlled cold storage; once reconstituted with bacteriostatic water it is more fragile and typically usable for a limited number of weeks refrigerated, away from heat and light. That window is measurable and product-specific, and supplier stability data is the correct reference — unlike the human cycle figures.
Reconstitution & storage →Research-use framing
Everything here describes protocol conventions and observations from the peptide literature, reproduced as a research reference for laboratory and in-vitro modelling — not instructions for human use, and not a claim of an optimal dosing schedule or efficacy in people. TB-500 is an investigational research compound without regulatory approval as a therapeutic. Titan supplies it strictly as a research reagent, not for human or animal consumption, and nothing here is medical or dosing advice.
Lab testing & COA workflow →The detail, in plain terms
TB-500 cycle length, separated into kinetics and convention.
A plain-terms split between the kinetic reasoning behind TB-500's loading/maintenance shape and the point where controlled evidence runs out — including the fragment-versus-parent-peptide distinction most pages skip. Reproduced as a research reference, not a human-use schedule.
- Validated human cycle length
- None for the TB-500 fragment. No fragment-specific controlled human trial has defined an optimal cycle or on/off schedule.
- Common protocol shape
- ~4–6 weeks higher-frequency 'loading' → lower-frequency 'maintenance' → rest. A convention inferred from kinetics, not a trial result.
- Why the two phases
- Prolonged tissue persistence: front-load to reach a working level, then dose less often to hold it. Inference, not proof.
- Kinetic profile
- Short plasma presence vs long tissue residence — the same feature that justifies loading also cautions against open-ended use.
- Fragment vs parent peptide
- Most cited human safety/duration data is full-length Thymosin β4 (e.g. RGN-259), NOT the TB-500 fragment. Do not conflate.
- Lab-controllable duration
- Reconstituted-vial viability: months lyophilised cold-stored; a limited number of weeks once reconstituted and refrigerated.
- Contrast — BPC-157
- BPC-157's cycling is caution-based (missing long-term data); TB-500's shape is genuinely half-life-driven. Different logic.
- Research framing
- All durations are protocol conventions / literature observations, not translatable to human protocols without controlled trials.
Questions researchers ask
Before you order.
- How long should a TB-500 cycle be?
- There is no fragment-specific, research-validated answer. No controlled human trial of the TB-500 fragment has established an optimal cycle length. The commonly-cited structure — roughly 4–6 weeks of higher-frequency 'loading' followed by a lower-frequency 'maintenance' phase and then a break — is protocol convention. It is coherent with the compound's kinetics but not proven by a trial, and this page is a research reference summarising that convention, not a human-use schedule.
- Why is TB-500 dosed in a loading and maintenance phase?
- Because of its kinetics. TB-500 is associated with a short plasma presence but prolonged tissue persistence, so the convention is to 'load' at a higher weekly frequency for the first several weeks to reach a working tissue level, then drop to a lower-frequency 'maintenance' phase to sustain it. That reasoning is a genuine inference from the half-life — which distinguishes it from BPC-157, whose cycling convention is caution-based rather than kinetic — but it remains an inference, not a trial-validated schedule.
- Is the cycle-length data actually from TB-500 or from Thymosin β4?
- Usually the latter, and this matters. TB-500 is a short synthetic fragment (Ac-LKKTETQ, residues 17–23 of Thymosin β4). Most of the controlled human safety and duration evidence people quote belongs to full-length Thymosin β4 — a different, larger molecule studied in programs such as RGN-259. Extrapolating those durations to the fragment is a leap most vendor pages make without saying so. Any TB-500 cycle figure claimed to be clinically-backed is very likely borrowing the parent peptide's record.
- What TB-500 duration can actually be controlled in a lab?
- Reconstituted-material stability. Lyophilised TB-500 reference material is stable for months under controlled cold storage, but once reconstituted with bacteriostatic water it becomes more fragile and is typically usable for a limited number of weeks refrigerated, away from heat and light. That window is measurable and product-specific, and supplier stability data is the appropriate reference — making it the one 'duration' question with a real, controllable answer, unlike the human cycle figures.
- Is TB-500 approved for human use?
- No. TB-500 is an investigational research compound without regulatory approval as a therapeutic, and it is on the WADA prohibited list at all times in sport. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The cycle-length information here summarises protocol conventions and literature observations and is not medical or dosing advice.